About TPD Assay Development & Screening
Developing improved assays and screening techniques is the pathway to discovering new degraders – do you agree?
Targeted Protein Degradation (TPD) has emerged as an exciting new modality in small molecule drug discovery with more degraders in the clinic than ever before. Despite this, degrader R&D is currently limited by low-throughput screening tools, a lack of robustness, and reproducibility. Furthermore, our understanding of target and degrader mode of action is languishing, and fresh insight is urgently needed.
With proof of concept and proof of biology now a reality for TPD, the time has come to revamp the toolbox to accelerate degrader R&D and address the pressing need for improved high-throughput screening methods for monitoring TPD that are efficient, robust, sensitive, quantifiable, and reproducible.
Top Sessions You Missed:
Unravel the mechanism of action of novel targets and degrader compounds to determine the best candidate for your chosen indication. Hear from Kymera Therapeutics, Pfizer, and Origami Therapeutics as they disclose insight into their biophysical and biochemical assays that have unveiled novel understanding
Establish a framework for rational structure-based drug design and master the tools used for ternary complex formation including Cryo-EM and AI with BMS & A-Alpha Bio
Unlock the full power of proteomics and genomics across your entire drug discovery pipeline through real-world examples with AbbVie & Pfizer and feel confident in progressing your compound with robust identification and validation
Realize the potential use of novel high throughput assays in discovering and distinguishing ‘ligandable’ targets and neo-substrates to expand your potential degrader landscape with Plexium & The Structural Genomics Consortium